These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25538783)

  • 1. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.
    Afshar H; Akuchekian S; Mahaky B; Zarean E
    J Res Med Sci; 2014 Oct; 19(10):976-81. PubMed ID: 25538783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial.
    Mowla A; Khajeian AM; Sahraian A; Chohedri AH; Kashkoli F
    CNS Spectr; 2010 Nov; 15(11):613-7. PubMed ID: 24726048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Afshar H; Roohafza H; Mohammad-Beigi H; Haghighi M; Jahangard L; Shokouh P; Sadeghi M; Hafezian H
    J Clin Psychopharmacol; 2012 Dec; 32(6):797-803. PubMed ID: 23131885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Shannahoff-Khalsa D; Fernandes RY; Pereira CAB; March JS; Leckman JF; Golshan S; Vieira MSR; Polanczyk GV; Miguel EC; Shavitt RG
    Front Psychiatry; 2019; 10():793. PubMed ID: 31780963
    [No Abstract]   [Full Text] [Related]  

  • 8. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
    Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
    J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
    Khalkhali M; Aram S; Zarrabi H; Kafie M; Heidarzadeh A
    Iran J Psychiatry; 2016 Apr; 11(2):104-14. PubMed ID: 27437007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
    Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
    Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
    [No Abstract]   [Full Text] [Related]  

  • 14. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
    Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
    Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
    JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial.
    Mowla A; Ghaedsharaf M
    CNS Spectr; 2020 Aug; 25(4):552-556. PubMed ID: 31648655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.
    Denys D; van Megen HJ; van der Wee N; Westenberg HG
    J Clin Psychiatry; 2004 Jan; 65(1):37-43. PubMed ID: 14744166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of Gamma Knife anterior capsulotomy for refractory obsessive-compulsive disorder: results in a series of 10 consecutive patients.
    Spatola G; Martinez-Alvarez R; Martínez-Moreno N; Rey G; Linera J; Rios-Lago M; Sanz M; Gutiérrez J; Vidal P; Richieri R; Régis J
    J Neurosurg; 2018 Sep; 131(2):376-383. PubMed ID: 30215566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
    Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.